Companies /Healthcare
Bristol-Myers Squibb Company
NYSE: BMY Drug Manufacturers - General
$61.35
▼ $1.58 (−2.51%) today
Markets closed · 7:05am ET

Bristol-Myers Squibb (BMY) Q3 2026 Earnings

Reported Oct 29, 2026, 7:05am ET · SEC source
$1.35
Beat +9.48%
EPS · est. $1.23 Adjusted

Non-GAAP EPS includes a $(0.58) per share net impact from Acquired IPRD charges ($1,558 million) and licensing income; gross margin also reflects a one-time contract termination charge. GAAP EPS of $1.05 additionally reflects $606 million of after-tax specified items, including $458 million amortization of acquired intangibles and $187 million restructuring provision.

$13.1B
Beat +2.67%
Revenue · est. $12.7B
7 quarters
Consecutive EPS beats

How Did BMY Stock React to Q3 2026 Earnings?

% change · around the report
−2%0+2%Oct 29Oct 30report 7:05am ETearnings−2.0%+2.1%
−2%0+2%Oct 29Oct 30earnings−2.0%+2.1%
BMY +2.1%S&P 500 −2.0%
−3%0+3%Oct 29Oct 30report 7:05am ETearnings−4.1%+2.1%
−3%0+3%Oct 29Oct 30earnings−4.1%+2.1%
BMY +2.1%NASDAQ −4.1%
−3%0+3%Oct 28Nov 6report 7:05am ETearnings−4.6%−0.4%
−3%0+3%Oct 28Nov 6earnings−4.6%−0.4%
BMY −0.4%S&P 500 −4.6%
−10%−5%0+5%Oct 28Nov 6report 7:05am ETearnings−8.4%−0.4%
−10%−5%0+5%Oct 28Nov 6earnings−8.4%−0.4%
BMY −0.4%NASDAQ −8.4%
+1.35%
Day of report
+1.78%
Next session
+2.83%
One week

Did BMY Beat Earnings? Q3 2026 Results

Yes. Bristol-Myers Squibb reported Q3 2026 earnings of $1.35 a share on Oct 29, 2026, beating the $1.23 consensus estimate by 9.5%. Revenue was $13.1B against a $12.7B estimate.

Bristol Myers Squibb delivered a strong third quarter of 2026, posting adjusted non-GAAP EPS of $1.35 against a consensus estimate of $1.23, a beat of 9.48% that extended the company's winning streak to six consecutive quarters of topping EPS expectations. Revenue climbed 6.9% year over year to $13.07 billion, ahead of the $12.73 billion consensus by 2.67%, powered chiefly by a surging Growth Portfolio that rose 12% to $7.66 billion, with Opdivo Qvantig more than tripling to $334 million and Eliquis jumping 25% to $4.69 billion on robust U.S. demand. Those gains helped offset steep generic-driven declines in Revlimid and Pomalyst, while $1.56 billion in Acquired IPRD charges, net of licensing income, weighed a combined $0.58 on EPS. GAAP gross margin contracted to 68.3% from 71.9%, partly due to a one-time contract termination charge. Looking ahead, management raised full-year revenue guidance to roughly $49.75 billion to $50.25 billion while trimming non-GAAP EPS guidance to $6.35 to $6.55, reflecting the ongoing IPRD and licensing headwind.

Key Takeaways
  • Growth Portfolio revenue rose 12%, led by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag.
  • Eliquis grew 25% worldwide and 39% in the U.S. on demand growth and market share gains.
  • Breyanzi gained adoption in the community outpatient setting.
  • Camzyos showed strong launch momentum outside the U.S., with international sales up 111%.
  • Generic erosion weighed on Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
  • Gross margin fell on product mix and a one-time contract termination charge.
  • SG&A fell 5% and GAAP R&D fell 6%.
  • The effective tax rate dropped to 14.1% (non-GAAP) on jurisdictional earnings mix.
  • Acquired IPRD charges of $1.6 billion reduced EPS by a net $(0.58).

“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio.”

Bristol-Myers Squibb CEO, on the earnings call

What Is Bristol-Myers Squibb's Outlook?

BMS raised full-year 2026 non-GAAP revenue guidance to approximately $49.75–$50.25 billion, from $49.0–$50.0 billion, citing broad-based momentum. It lowered non-GAAP diluted EPS guidance to $6.35–$6.55, from $6.75–$7.00, inclusive of a $(0.60) impact from Acquired IPRD and licensing income. Other guidance: - Gross margin of ~69–70%, unchanged. - Operating expenses of ~$16.5 billion, unchanged. - Other income/(expense) of ~$(650) million, improved from ~$(700) million on favorable net interest. - Tax rate of ~18%, unchanged. - Worldwide Eliquis revenue growth of 20–25%. - Legacy Portfolio decline of 3–5%. - Diluted share count of 2,051 million. Upcoming catalysts include Zenbexus Phase 3 PFS data and golcadomide Phase 2 data at ASH, and a mezigdomide PDUFA date of May 13, 2027.

BMY YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$4.0B$8.0B$12.0B$12.2B$13.1BRevenue$2.2B$2.2BNet Income
$0$4.0B$8.0B$12.0BRevenueNet Income
BMY income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $13.1B $12.2B +6.9%
Net Income $2.2B $2.2B −1.8%

BMY Revenue by Segment

Eliquis$4.7B+25.0%
Opdivo$2.4B−6.0%
Orencia$983.0M+2.0%
Revlimid$303.0M−47.0%
Yervoy$793.0M+7.0%
Reblozyl$750.0M+22.0%
Pomalyst/Imnovid$130.0M−81.0%
Breyanzi$526.0M+46.0%

BMY Revenue by Geography

United States$9.1B+9.0%
Rest of World$4.0B+3.0%

When Does Bristol-Myers Squibb Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.